Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen

Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
--Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to a potential value of $200 million --Inspiration grants Ipsen commercial rights to hemophilia drug candidates IB1001 and OBI-1 in certain geographies --Inspiration gains the ability to develop as an independent company

CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire via COMTEX/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen. The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of these agreements, Inspiration grants Ipsen commercialization rights for IB1001 (recombinant human factor IX) and OBI-1 (recombinant porcine factor VIII) in certain geographies. Inspiration will receive a $30 million up-front payment, with additional payments and investments linked to future development and commercial milestones, for a total potential value of $200 million. This includes a commitment from Ipsen to fund a significant percentage of Inspiration's next round of external financing.

Ipsen gains rights to commercialize IB1001 and OBI-1 in Europe, Russia, China, Australia and certain other countries, and will be responsible for future regulatory filings in those regions. Inspiration retains commercialization rights in the Americas, Japan, India, the Middle East, South Africa, Taiwan and certain other countries, as well as global development rights for all products in Inspiration's product portfolio. Each company is obligated to pay the other royalties generated by sales of OBI-1 in their respective geographies and Ipsen will pay Inspiration royalties on sales of IB1001.

Under the terms of the new agreements, after the completion of a $30 million qualified external financing Ipsen will invest an additional $20 million in Inspiration and will no longer have a call option to acquire Inspiration, giving Inspiration the ability to develop as an independent entity. Ipsen gains the right to appoint two additional Directors to Inspiration's Board.

"During the last two years, Ipsen's commitment to hemophilia and their recognition of the value of Inspiration's unique product portfolio have been the basis for a successful collaboration," said John P. Butler, Chief Executive Officer of Inspiration. "This new arrangement confirms Ipsen's ongoing commitment to Inspiration, while also enabling Inspiration to become an independent, fully integrated, commercial biopharmaceutical company serving people living with hemophilia."

Inspiration and Ipsen's strategic partnership began in January 2010, and in August of 2011 was expanded in preparation for the commercial launch of Inspiration's first hemophilia products in Europe. The 2011 agreement established a European commercial partnership, which was designed to leverage the combined strengths of Ipsen's well-established European commercial infrastructure and medical network with Inspiration's expertise in the field of hemophilia. The new agreements announced today will replace the previous European commercial partnership agreement.

About Inspiration Biopharmaceuticals

As the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care, and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration's lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com .

 

        For Further Information
        Media                         Investors
        Dan Quinn                     Gordon H. Busenbark
        Feinstein Kean Healthcare     Senior Vice President, Chief Financial Officer
        Tel: +1-617-577-8110          Tel: +1-617-588-1802
        Email: [email protected]
       


SOURCE Inspiration Biopharmaceuticals, Inc.

Suggested Articles

Kadmon has posted positive and more detailed data out of its so-called ROCKstar pivotal trial of KD025 in chronic graft-versus-host disease.

Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells.

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.